Back to search

Article

Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants

2026-01-14

Abstract excerpt

<title>Abstract</title> <p>Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). To address this issue, we developed a novel therapeutic strategy based on multiparatopic antibodies that induce targeted degradation of EGFR, independent of driver mutations typically residing in the cytosolic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
44c718bd-8f6c-5728-ae5c-e2cf80aa67a3
DOI
10.21203/rs.3.rs-8437918/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutantsDOI 10.21203/rs.3.rs-8437918/v1
Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Semantic proximity
Multispecific nanobody degraders co-deplete membrane receptors and enable targeted delivery of diverse payloadsSemantic proximity
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.Semantic proximity
Targeting EGFR degradation by autophagosome degraders.Semantic proximity
Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity
Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.Semantic proximity
Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer.Semantic proximity
Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.Semantic proximity
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.Semantic proximity
A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor ModelsSemantic proximity
Multibody-Enabled Lysosome-Targeting Drug Conjugates for Target Protein Degradation and Combination TherapySemantic proximity
Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity
Select a neighboring publication to make it the new centre.